Increased concentration of soluble CD40 ligand in preeclampsia

Clinical and Applied Thrombosis/Hemostasis

Volumn 13, Issue 2, 2007, Pages 201-205

  Alacacioglu, Inci ^a   Ozcan, Mehmet Ali ^a   Piskin, Ozden ^a   Yuksel, Faize ^a   Alacacioglu, Ahmet ^a   Demirkan, Fatih ^a   Ozsan, Hayri Guner ^a   Polat, Mesut ^b   Ozgenc, Yigit ^b   Undar, Bulent ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b Tepecik S S K Maternity Hospital   (Turkey)

Author keywords

Inflammation; Preeclampsia; Soluble CD40 ligand

Indexed keywords

CD40 LIGAND;

ADULT; ANTIGEN DETECTION; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HEMOSTASIS; HUMAN; INFLAMMATION; MALE; PATHOGENESIS; PREECLAMPSIA; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THROMBOCYTE ACTIVATION; THROMBOSIS;

ADULT; CD40 LIGAND; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; SOLUBILITY;

EID: 34047270582     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029606299076     Document Type: Article

References (28)

1. Martin L., Pernoll RC Current Obstetric and Gynecologic Diagnosis and Treatment. 6 th ed. Norwalk, CT: Appleton & Lange ; 1987.
2. Dizon-Townson D., Branch DW Anticoagulant treatment during pregnancy: an update. Semin Thromb Hemost. 1998 ; 24 (suppl 1). 55-62.
3. Roberts JM, Redman Cwg. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet. 1993 ; 341: 1447-1451.
4. Redman CW, Sacks GP, Sargent IL Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol. 1999 ; 180: 499-506.
5. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol. 1989 ; 161: 1200-1204.
6. Janes SL, Kyle PM, Redman C., Goodall AH Flow cytometric detection of activated platelets in pregnant women prior to the development of preeclampsia. Thromb Haemost. 1995 ; 74: 1059-1063.
7. Henn V., Slupsky JR, Grafe M., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998 ; 391: 591-594.
8. Mellembakken JR, Solum NO, Ueland T., Videm V., Aukrust P. Increased concentrations of soluble CD40 ligand, RANTES and GRO-alpha in preeclampsia- possible role of platelet activation. Thromb Haemost. 2001 ; 86: 1272-1276.
9. Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol. 1998 ; 158: 892-898.
10. Ricci G., Cerneca F., Simeone R., et al. Coagulation and fibrinolytic parameters in normal and hypertensive pregnancies. J Matern Fetal Invest. 1997 ; 7: 129-132.
11. Gammaro L., Lippi G., Bottini E., et al. Severe preeclampsia in antithrombin III deficiency with no history of venous thromboembolism. J Nephrol. 2001 ; 14: 312-315.
12. Schjetlein R., Haugen G., Wisloff F. Markers of intravascular coagulation and fibrinolysis in preeclampsia: association with intrauterine growth retardation. Circulation. 1997 ; 96: 569-574.
13. Schjetlein R., Abdelnoor M., Haugen G., et al. Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia. Acta Obstet Gynecol Scand. 1999 ; 78: 191-197.
14. Carr DB, McDonald GB, Brateng D., Desai M., Thach CT, Easterling TR The relationship between hemodynamics and inflammatory activation in women at risk for preeclampsia. Obstet Gynecol. 2001 ; 98: 1109-1116.
15. Williams MA, Farrand A., Mittendorf R., Sorensen TK, Zingheim RW, O'Reilly GC Maternal second trimester serum tumor necrosis factor-alpha soluble receptor p55 (sTNFp55) and subsequent risk of preeclampsia. Am J Epidemiol. 1999 ; 149: 323-329.
16. Eneroth E., Remberger M., Vahlne A., Ringden O. Increased serum concentration of interleukin-2 receptor in the first trimester in women who later developed severe preeclampsia. Acta Obstet Gynecol. Scand. 1998 ; 77: 591-593.
17. Hamai Y., Fujii T., Yamashita T., Nishna H., Kasuma S., Mikami Y. Evidence for an elevation in serum interleukin-2 and tumor necrosis factor-alpha levels before the clinical manifestations of preeclampsia. Am J Reprod Immunol. 1997 ; 38: 89-93.
18. Sacks GP, Studena K., Sargent IL, Redman Cwg. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol. 1998 ; 179: 80-86.
19. Thilaganathan B., Makrydimas G., Plachouras N., Nicolaides KH Neutrophil and monocyte b2-integrin expression in maternal and fetal blood. Am J Obstet Gynecol. 1995 ; 172: 58-62.
20. Schonbeck U., Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci. 2001 ; 58: 4-43.
21. Lee Y., Lee WH, Lee SC, et al. CD40L activation in circulating platelets in patient with acute coronary syndrome. Cardiology. 1999 ; 92: 11-16.
22. Henn V., Steinbach S., Buchner K., Presek P., Kroczek RA The inflammatory action of CD40 ligand (CD 154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood. 2001 ; 98: 1047-1054.
23. Mach F., Schonbeck U., Bonnefoy IY, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation. 1997 ; 96: 396-399.
24. Urbich C., Mallat Z., Tedgui A., Clauss M., Zeiher AM, Dimmeler S. Upregulation of TRAF-3 by shear stress blocks CD40 mediated endothelial activation. J Clin Invest. 2001 ; 108: 1451-1458.
25. Buhlmann JE, Noelle RJ Therapeutic potential for blockade of the CD40 ligand, gp39. J Clin Immunol. 1996 ; 16: 83-89.
26. Miga A., Masters S., Gonzalez M., Noelle RJ The role of CD40-CD154 interactions in the regulation of cell mediated immunity. Immunol Invest. 2000 ; 29: 111-114.
27. Heeschen C., Dimmeler S., Hamm CW,, et al. CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003 ; 348: 1104-1111.
28. Andre P., Nannizzi-Alaimo L., Prasad SK, Phillips DR Platelet derived CD40L: the switch-hitting player of cardiovascular disease. Circulation. 2002 ; 106: 896-899.